X4 Pharmaceuticals Announces Strategic Restructuring With 50% Workforce Reduction Expected To Deliver $13M Annualized Cost Savings
Benzinga Newsdesk 1 year ago
News
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13MJohn Volpone appointed Chief Operating Officer, in addition to his current
- Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M
- John Volpone appointed Chief Operating Officer, in addition to his current role as President
- Dr. Adam Craig, Executive Chairman, to have oversight over clinical development